In addition, our design of a potentially bioactive CPPs based on VEZF1 glycosylation site, which competitively inhibits VEZF1 O-GlcNAcylation, shows therapeutic potential in vitro and in vivo, suggesting a future therapeutic application for liver cancer. The gene discussed is VEZF1; the disease is liver cancer.